Af­ter a bruis­ing year, Aeter­na Zen­taris inks a $24M up­front US pact for growth hor­mone as­set

Over the past year Aeter­na Zen­taris $AEZS has watched its lead drug go down in flames on a failed Phase III tri­al, gone back to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.